15 results about "Isosorbide mononitrate" patented technology

The present invention relates to a mononitroisosorbide derivative, its preparation method, and application. The derivative has the following structure: #imgabs0#, wherein R is one of the following structures: #imgabs1#. The mononitroisosorbide derivative is prepared by reacting 5-isosorbide mononitrate with an acyl chloride (sulfonyl chloride) compound in the presence of triethylamine and a catalyst, 4-dimethylaminopyridine. The mononitroisosorbide derivative exhibits excellent anti-tumor activity. Compared to existing technologies, the present invention designs and synthesizes multiple compounds with novel structures, among which ZM533 exhibits moderate anti-tumor activity against the A549 cell line and is expected to be used in the preparation of anti-lung cancer drugs.

The invention discloses a liver-targeting nitric oxide donor compound and application thereof. The compound is a derivative of 5-isosorbide mononitrate, and can be enriched in the liver and release nitric oxide. Compared with 5-isosorbide mononitrate, the compound disclosed by the invention is easier to metabolize after primary hepatocyte incubation of mice, effectively releases effector molecules such as nitric oxide and the like, shows good liver targeting, is expected to play a better effect in treatment of liver-related diseases, and improves the clinical application value of drugs.

The present application belongs to the technical field of mineral processing. The present application provides a flotation reagent for inhibiting calcite in fluorite-barite intergrowth ore, which comprises a collector and an inhibitor; the collector comprises at least one of sodium oleate and oxidized paraffin soap; the inhibitor comprises 5-mononitrate isosorbide and water glass in a weight ratio of 4-5:1. The present application also provides a corresponding flotation method, which comprises the steps of: preparing fluorite-barite intergrowth ore containing calcite into ore slurry, and then adding the collector and the inhibitor described in claim 1 or 2 to the obtained ore slurry for flotation. The present application can effectively inhibit calcite during the flotation of fluorite-barite intergrowth ore and improve the fluorite recovery rate, and the obtained CaF2 recovery rate is as high as 95% or more; the flotation reagent used in the present application has a small amount of use and low flotation cost.

The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula: 1 pantthenol of the following formula:2 and inositol of the following formula:3 or with isosorbide of the following formula:4 or isosorbide mononitrate of the following formula:5 It also relates to a method of preparation of same, a pharmaceutical composition same and the of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation.

The present invention belongs to the field of pharmaceuticals. Disclosed in the present invention are a class of salt compounds of isosorbide mononitrate derivatives and the use thereof. Salts formed by the isosorbide mononitrate derivatives of the present invention and D-cycloserine exhibit dual activities as a nitric oxide donor and a partial NMDA receptor agonist. The present invention further relates to the use of the salts formed by the isosorbide mononitrate derivatives and D-cycloserine in a drug for treating cerebral stroke or the recovery period of cerebral stroke.

The application belongs to the technical field of direct compression of pharmaceutical preparations, and particularly relates to a sustained-release isosorbide mononitrate tablet and a preparation method thereof. The sustained-release tablet is composed of a sustained-release tablet core and a coating layer. After isosorbide mononitrate, hydroxypropyl cellulose, palm wax, silicon dioxide, microcrystalline cellulose-lactose and talc powder are mixed, the powder is directly compressed into a tablet. The obtained tablet is coated into a film-coated tablet by using a moisture-proof coating material (AMB). The powder direct compression technology is adopted, so that the technical complexity is greatly reduced, and the wet heat unit operation is avoided. The preparation process is simple, and the quality is stable.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a mononitrate isosorbide oral dissolving film and a preparation method thereof. The mononitrate isosorbide oral dissolving film preparation is composed of a drug-containing layer and isolation layers which are compounded on the upper and lower surfaces of the drug-containing layer. The drug-containing layer comprises the following raw materials in percentage by mass: cyclodextrin-encapsulated mononitrate isosorbide 10-60%, film-forming material 20-80%, plasticizer 0-20% and auxiliary material 0-10%. The isolation layer comprises the following raw materials in percentage by mass: film-forming material 70-100%, plasticizer 0-30% and auxiliary material 0-10%. The mononitrate isosorbide oral dissolving film prepared by the application has the advantages of smooth appearance, good taste, uniform drug content, rapid dissolution under the action of saliva after entering the mouth, and further release and absorption, which greatly improves the drug administration compliance and solves the problem of surface crystallization of mononitrate isosorbide after long-term storage.

The invention discloses a method for detecting a related substance in an isosorbide mononitrate tablet, which comprises the following steps of: detecting the related substance isosorbide acetate in the isosorbide mononitrate tablet by adopting a high performance liquid chromatography, and eluting by taking octadecylsilane chemically bonded silica as a chromatographic column of a filler, buffer salt or water as a mobile phase A and methanol as a mobile phase B; the detection wavelength is 210 to 220 nm; and the sample size is 10-50 [mu] l. By utilizing the method, the separation degrees of peaks of the related substances isosorbide acetate and isosorbide mononitrate both reach 2.0 or above, and the recovery rates of impurities both meet the requirements of 80.0%-120.0%; the method has the advantages of high specificity and high sensitivity, and realizes better quality control of the isosorbide mononitrate tablets.

The utility model provides a high-speed rotary tablet press for isosorbide mononitrate sustained-release capsule medicaments, belongs to the technical field of pharmaceutical production, and aims to solve the problem that a rotary processing part is easy to hurt people when the rotary processing part is operated by the people at present. Comprising a tabletting main body, a tabletting rotating plate, an operation panel, an emergency stop switch, a protective rotating shaft, a shutdown pressing block, a protective plate switching mechanism and a maintenance shutdown mechanism, the tablet pressing part is arranged in the tablet pressing main body; the operation panel is fixedly connected to the right end face of the pressing piece body. The emergency stop switch is fixedly connected to the front side of the operation panel; the protective rotating shaft is rotationally connected to the interior of the pressing sheet main body; the shutdown pressing block is connected to the interior of the pressing sheet main body in a sliding manner; the protective plate switching mechanism is arranged in the tablet pressing main body; and the maintenance shutdown mechanism is arranged on the right side in the tabletting main body. By means of the protection plate opening and closing mechanism, personnel can maintain the tablet pressing part conveniently, and by means of the maintenance stopping mechanism, the safety of the personnel for maintaining the tablet press is guaranteed.

The invention discloses an isosorbide mononitrate osmotic pump controlled-release tablet and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. An isosorbide mononitrate osmotic pump controlled-release tablet of the invention comprises a booster layer, wherein drug-containing layers are arranged above and below the booster layer, and the booster layer and the drug-containing layer are wrapped with a semipermeable membrane coating layer, and the semipermeable membrane coating layer is provided with drug-releasing holes. The isosorbide mononitrate osmotic pump controlled-release tablet of the invention has a three-layer tablet core structure of "drug-containing layer-boosting layer-drug-containing layer", and drug-releasing holes are provided in the semipermeable membrane coating layer to achieve a sustained-release effect, so that the dissolution amount increases slowly, the sustained-release effect is good, the release is stable, the effect is long-lasting, and multiple administrations can be avoided.

The present application provides a kind of isosorbide mononitrate sustained-release capsules and its preparation method, the isosorbide mononitrate sustained-release capsule of the present application, characterized in that, the drug loading layer, sustained-release layer, immediate-release layer and protective layer of the isosorbide mononitrate sustained-release capsule are respectively coated by fluidized bed granulation coating machine.The granular preparation has good stability, small side effect;The preparation process of the isosorbide mononitrate sustained-release capsule of the present application is simple, the equipment is simple and easy to operate, the labor intensity is small, and it is economic and safe.At the same time, the prescription and preparation method are more economical, and are suitable for industrial production.

The application discloses L-alanine crystals and a preparation method thereof, relates to the technical field of L-alanine crystal preparation, and is characterized in that a morphology regulator is added into an aqueous solution containing L-alanine, crystallization is performed, and L-alanine crystals are obtained; the morphology regulator comprises any one or a combination of more than one of paclitaxel, isosorbide mononitrate and lactic acid. In the application, the morphology regulator is added into the aqueous solution containing L-alanine, the growth of the long axis of the crystals is inhibited, the growth of the short axis is promoted, and short rod-shaped L-alanine crystals are obtained. The application has the advantages of simple process, easy control and environmental protection.

The invention relates to an application of a coating premix in an isosorbide mononitrate tablet and the isosorbide mononitrate tablet. The coating premix is prepared from the following components in parts by weight: 40 to 60 parts of eudragit RS100, 20 to 30 parts of eudragit RL100, 10 to 15 parts of plasticizer, 15 to 20 parts of coloring agent, 15 to 20 parts of anti-sticking agent and 500 to 600 parts of solvent; the eudragit RS100 is prepared from ethyl acrylate, methyl methacrylate and methacrylic acid chlorinated trimethylamine ethyl ester; the eudragit RL100 is prepared from ethyl acrylate, methyl methacrylate and methacrylic acid chlorinated trimethylamine ethyl ester; through the application of the coating premix in the isosorbide mononitrate tablet, the technical problems that the existing isosorbide mononitrate tablet cannot be disintegrated and released after reaching the ileocecum of a human body, and the bioavailability of the medicine cannot be ensured are solved.

The invention belongs to the technical field of chronic disease medicine preparations, and particularly relates to an isosorbide mononitrate composition, a preparation method and application. The isosorbide mononitrate composition disclosed by the invention is prepared from isosorbide mononitrate and a hairyvein agrimony extract. According to the invention, the isosorbide mononitrate and the hairyvein agrimony extract are combined for use, so that the effect of synergistically treating the coronary heart disease is achieved, the release speed of the isosorbide mononitrate is delayed, and the long-acting release of the medicine can be maintained.

The invention relates to the technical field of drug analysis and detection, and particularly discloses a method for detecting related substances in an isosorbide mononitrate sodium chloride injection and application of the method. The invention provides a method for detecting related substances in an isosorbide mononitrate sodium chloride injection. The method comprises the following steps: preparing a mixed reference solution, preparing a test solution and carrying out liquid chromatography detection, wherein the liquid chromatography detection adopts a mobile phase gradient elution procedure, a mobile phase A is methanol-water, and a mobile phase B is ethanol-trimethylpentane; furthermore, the volume ratio of methanol to water in the mobile phase A is (25-30): (70-75), and the volume ratio of ethanol to trimethylpentane in the mobile phase B is (15-20): (80-85). According to the detection method provided by the invention, the contents of isosorbide mononitrate, 2-isosorbide mononitrate and isosorbide dinitrate in the isosorbide mononitrate sodium chloride injection can be rapidly and accurately detected, and the detection sensitivity and accuracy are high.